Carregant...
Biological Drugs in Guillain-Barré Syndrome: An Update
BACKGROUND: Guillain-Barré Syndrome (GBS) is currently considered the most common global cause of acute flaccid paralysis. Currently, standard therapy for Guillain-Barré Syndrome includes intravenous immunoglobulin or plasma exchange. Despite medical advances regarding these treatments, many treated...
Guardat en:
| Publicat a: | Curr Neuropharmacol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Bentham Science Publishers
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5652014/ https://ncbi.nlm.nih.gov/pubmed/27964705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1570159X14666161213114904 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|